Your browser doesn't support javascript.
Update on SARS-CoV-2 seroprevalence: regional and worldwide.
Rostami, Ali; Sepidarkish, Mahdi; Fazlzadeh, Aylar; Mokdad, Ali H; Sattarnezhad, Aida; Esfandyari, Sahar; Riahi, Seyed Mohammad; Mollalo, Abolfazl; Dooki, Mohammadreza Esmaeili; Bayani, Masomeh; Nazemipour, Maryam; Mansournia, Mohammad Ali; Hotez, Peter J; Gasser, Robin B.
  • Rostami A; Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Electronic address: alirostami1984@gmail.com.
  • Sepidarkish M; Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran.
  • Fazlzadeh A; Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mokdad AH; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
  • Sattarnezhad A; Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, Cyprus.
  • Esfandyari S; Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
  • Riahi SM; Cardiovascular Diseases Research Center, Department of Epidemiology and Biostatistics, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
  • Mollalo A; Department of Public Health and Prevention Science, School of Health Sciences, Baldwin Wallace University, Berea, OH, USA.
  • Dooki ME; Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
  • Bayani M; Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
  • Nazemipour M; Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Mansournia MA; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Hotez PJ; Texas Children's Hospital Center for Vaccine Development, Department of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
  • Gasser RB; Department of Veterinary Biosciences, Melbourne Veterinary School, Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Parkville, Victoria, Australia. Electronic address: robinbg@unimelb.edu.au.
Clin Microbiol Infect ; 27(12): 1762-1771, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1433091
ABSTRACT

BACKGROUND:

With limited vaccine supplies, an informed position on the status of SARS-CoV-2 infection in people can assist the prioritization of vaccine deployment.

OBJECTIVES:

We performed a systematic review and meta-analysis to estimate the global and regional SARS-CoV-2 seroprevalences around the world. DATA SOURCES We systematically searched peer-reviewed databases (PubMed, Embase and Scopus), and preprint servers (medRxiv, bioRxiv and SSRN) for articles published between 1 January 2020 and 30 March 2021. STUDY ELIGIBILITY CRITERIA Population-based studies reporting the SARS-CoV-2 seroprevalence in the general population were included.

PARTICIPANTS:

People of different age groups, occupations, educational levels, ethnic backgrounds and socio-economic status from the general population.

INTERVENTIONS:

There were no interventions.

METHODS:

We used the random-effects meta-analyses and empirical Bayesian method to estimate the pooled seroprevalence and conducted subgroup and meta-regression analyses to explore potential sources of heterogeneity as well as the relationship between seroprevalence and socio-demographics.

RESULTS:

We identified 241 eligible studies involving 6.3 million individuals from 60 countries. The global pooled seroprevalence was 9.47% (95% CI 8.99-9.95%), although the heterogeneity among studies was significant (I2 = 99.9%). We estimated that ∼738 million people had been infected with SARS-CoV-2 (as of December 2020). Highest and lowest seroprevalences were recorded in Central and Southern Asia (22.91%, 19.11-26.72%) and Eastern and South-eastern Asia (1.62%, 1.31-1.95%), respectively. Seroprevalence estimates were higher in males, persons aged 20-50 years, in minority ethnic groups living in countries or regions with low income and human development indices.

CONCLUSIONS:

The present study indicates that the majority of the world's human population was still highly susceptible to SARS-CoV-2 infection in mid-2021, emphasizing the need for vaccine deployment to vulnerable groups of people, particularly in developing countries, and for the implementation of enhanced preventive measures until 'herd immunity' to SARS-CoV-2 has developed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Seroepidemiologic Studies / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Seroepidemiologic Studies / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2021 Document Type: Article